| Drug General Information |
| Drug ID |
D0T4BL
|
| Former ID |
DCL000008
|
| Drug Name |
Neovastat
|
| Indication |
Non-small-cell lung cancer; Renal cell carcinoma [ICD9: 140-229, 162, 162.9, 189, 204.0; ICD10:C33, C33-C34, C34, C34.90, C64, C91.0]
|
Phase 1 |
[1]
|
|---|
| Therapeutic Class |
Anticancer Agents
|
| Company |
Ferrer; Hospira; LG Life Sciences; AEterna Zentaris
|
| CAS Number |
CAS 305838-77-1
|
| Target and Pathway |
| Target(s) |
MMP-9 |
Target Info |
Inhibitor |
[2],
[3],
[4]
|
|---|
| MMP-12 |
Target Info |
Inhibitor |
[2],
[3],
[4]
|
| 72 kDa type IV collagenase |
Target Info |
Inhibitor |
[2],
[3],
[4]
|
|
KEGG Pathway
|
TNF signaling pathway
|
|
Leukocyte transendothelial migration
|
|
Estrogen signaling pathway
|
|
Hepatitis B
|
|
Pathways in cancer
|
|
Transcriptional misregulation in cancer
|
|
Proteoglycans in cancer
|
|
MicroRNAs in cancer
|
|
Bladder cancerhsa04670:Leukocyte transendothelial migration
|
|
GnRH signaling pathway
|
|
Bladder cancer
|
|
NetPath Pathway
|
ID Signaling Pathway
|
|
TWEAK Signaling Pathway
|
|
Leptin Signaling Pathway
|
|
TNFalpha Signaling PathwayNetPath_13:IL1 Signaling Pathway
|
|
IL5 Signaling PathwayNetPath_22:Leptin Signaling Pathway
|
|
TCR Signaling Pathway
|
|
PANTHER Pathway
|
Alzheimer disease-presenilin pathway
|
|
Plasminogen activating cascade
|
|
CCKR signaling map STP00004:Alzheimer disease-presenilin pathway
|
|
Pathway Interaction Database
|
LPA receptor mediated events
|
|
Plasma membrane estrogen receptor signaling
|
|
Osteopontin-mediated events
|
|
Validated transcriptional targets of AP1 family members Fra1 and Fra2
|
|
Validated targets of C-MYC transcriptional activation
|
|
CXCR4-mediated signaling events
|
|
amb2 Integrin signaling
|
|
Syndecan-4-mediated signaling events
|
|
AP-1 transcription factor network
|
|
Urokinase-type plasminogen activator (uPA) and uPAR-mediated signaling
|
|
Syndecan-1-mediated signaling events
|
|
Regulation of nuclear beta catenin signaling and target gene transcription
|
|
FGF signaling pathwayupa_upar_pathway:Urokinase-type plasminogen activator (uPA) and uPAR-mediated signalinglysophospholipid_pathway:LPA receptor mediated events
|
|
Angiopoietin receptor Tie2-mediated signaling
|
|
Direct p53 effectors
|
|
ATF-2 transcription factor network
|
|
FOXM1 transcription factor network
|
|
Syndecan-2-mediated signaling events
|
|
Reactome
|
Collagen degradation
|
|
Degradation of the extracellular matrix
|
|
Activation of Matrix Metalloproteinases
|
|
Assembly of collagen fibrils and other multimeric structures
|
|
EPH-ephrin mediated repulsion of cellsR-HSA-1442490:Collagen degradation
|
|
Degradation of the extracellular matrixR-HSA-1442490:Collagen degradation
|
|
Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs)
|
|
EPH-ephrin mediated repulsion of cells
|
|
WikiPathways
|
Endochondral Ossification
|
|
IL1 and megakaryotyces in obesity
|
|
Mammary gland development pathway - Involution (Stage 4 of 4)
|
|
Activation of Matrix Metalloproteinases
|
|
Degradation of collagen
|
|
Spinal Cord Injury
|
|
AGE/RAGE pathway
|
|
TWEAK Signaling Pathway
|
|
Angiogenesis
|
|
Osteopontin Signaling
|
|
Matrix MetalloproteinasesWP366:TGF beta Signaling Pathway
|
|
Matrix MetalloproteinasesWP2769:Activation of Matrix Metalloproteinases
|
|
Matrix Metalloproteinases
|
| References |
| REF 1 | Emerging therapies for multiple myeloma. Expert Opin Emerg Drugs. 2009 Mar;14(1):99-127. |
|---|
| REF 2 | Neovastat, a naturally occurring multifunctional antiangiogenic drug, in phase III clinical trials. Semin Oncol. 2001 Dec;28(6):620-5. |
|---|
| REF 3 | The effect of Neovastat (AE-941) on an experimental metastatic bone tumor model. Int J Oncol. 2002 Feb;20(2):299-303. |
|---|
| REF 4 | Neovastat (AE-941) inhibits the airway inflammation and hyperresponsiveness in a murine model of asthma. J Microbiol. 2005 Feb;43(1):11-6. |
|---|
